It’s caused by a mutation in a gene that codes for a protein called dystrophin. The disease mostly affects boys, and symptoms usually start in early childhood. At first, affected children usually start to find it hard to jump or climb stairs. The FDA approval was granted on the condition that Sarepta complete another clinical trial. The topline results of that trial were described in October 2023 and were published in detail a year later.